Paper Details

  1. Home
  2. Paper Details

Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.

Author: ChapmanRichard W, ChenKuan-Ju, CorbozMichel R, KonicekDonna M, LaurentCharles E, LeiferFranziska G, LiZhili, PerkinsWalter R, PlauntAdam J, S MalininVladimir, SalvailDany

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

To improve the side effects and reduce the dosing frequency of treprostinil (TRE), an inhaled slow-release formulation was designed. This formulation involved chemically modifying TRE to be an alkyl prodrug (TPD) and packaging it into a lipid nanoparticle (LNP) carrier. The TPD-LNP demonstrated a 10-fold lower TRE plasma Cmax compared to inhaled TRE solution while maintaining an extended vasodilatory effect. This sustained presentation of TRE could allow for a once- or twice-daily dosing schedule without the high Cmax-associated adverse events.
Paper Details　
Original Abstract of the Article :
Treprostinil (TRE), a prostanoid analogue approved in the USA for the treatment of pulmonary arterial hypertension, requires continuous infusion or multiple dosing sessions per day for inhaled and oral routes of administration due to its short half-life. The inhaled drug is known to induce adverse s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0044-100374

データ提供：米国国立医学図書館（NLM）

Inhaled Treprostinil: A New Approach to Pulmonary Vasodilation

Pulmonary arterial hypertension (PAH) is a serious condition that affects the blood vessels in the lungs. This study focuses on treprostinil, a drug used to treat PAH, and investigates a novel delivery method using inhaled lipid nanoparticles. Imagine a desert traveler carrying a precious resource, like water, in a carefully designed container to ensure optimal delivery.

Delivering Treprostinil More Effectively

The researchers have developed a new approach to treprostinil delivery that aims to reduce side effects and improve patient compliance. The use of inhaled lipid nanoparticles allows for a sustained release of the drug, potentially leading to fewer dosage requirements and less discomfort for patients. This approach represents a significant advancement in PAH treatment.

Implications for PAH Treatment

The findings of this study could transform PAH treatment by providing patients with a more convenient and tolerable option. This could lead to improved quality of life for individuals living with this challenging condition.

Dr. Camel's Conclusion

This study is a testament to the power of innovation in medicine. By exploring new delivery methods for existing drugs, researchers are paving the way for more effective and patient-centered treatments for pulmonary arterial hypertension.

Date :
  1. Date Completed 2019-01-28
  2. Date Revised 2019-01-28
Further Info :

Pubmed ID

29791923

DOI: Digital Object Identifier

10.1055/s-0044-100374

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.